Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member under age 65, please register here.

If you are an Medicare or Medicare Supplement member, please register here.

New Options for Affordable Health Insurance


MP 6.01.40 Whole Body Dual X-Ray Absorptiometry (DEXA) to Determine Body Composition

Medical Policy




Original Policy Date

Last Review Status/Date
reviewed with literature


  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.


Using low dose x-rays of two different energy levels, whole body dual x-ray absorptiometry (DEXA) measures lean tissue mass and total and regional body fat, as well as bone density.

Measurements of body composition have been used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of aging, obesity, and various wasting conditions such as occurs with acquired immune deficiency syndrome (AIDS) or post-bariatric surgery. A variety of techniques has been researched, including most commonly, anthropomorphic measures, bioelectrical impedance, and dual x-ray absorptiometry (DEXA) scans. All of these techniques are based in part on assumptions regarding the distribution of different body compartments and their density, and all rely on formulas to convert the measured parameter into an estimate of body composition. Therefore, all techniques will introduce variation based on how the underlying assumptions and formulas apply to different populations of subjects, i.e., different age groups, ethnicities, or underlying conditions. Anthropomorphic, bioimpedance, and DEXA techniques are briefly reviewed as followed.

Anthropomorphic Techniques

Anthropomorphic techniques for the estimation of body composition include measurements of skin-fold thickness at various sites, bone dimensions, and limb circumference. These measurements are used in various equations to predict body density and body fat. Due to its ease of use, measurement of skin-fold thickness is one of the most commonly used techniques. The technique is based on the assumption that the subcutaneous adipose layer reflects total body fat, but this association may vary with age and gender.

Bioelectrical Impedance

Bioelectrical impedance is based on the relationship between the volume of the conductor (i.e., the human body), the conductor's length (i.e., height), the components of the conductor (i.e., fat and fat-free mass), and its impedance. Estimates of body composition are based on the assumption that the overall conductivity of the human body is closely related to lean tissue. The impedance value is then combined with anthropomorphic data to give body compartment measures. The technique involves attaching surface electrodes to various locations on the arm and foot. Alternatively, the patient can stand on pad electrodes.

Underwater Weighing

Underwater weighing (UWW) has generally been considered the reference standard for body composition studies. This technique requires the use of a specially constructed tank in which the subject is seated on a suspended chair. The subject is then submerged in the water while exhaling. While valued as a research tool, UWW is obviously not suitable for routine clinical use. UWW is based on the assumption that the body can be divided into 2 compartments with constant densities, i.e., adipose tissue with a density of 0.9g/cm3 and lean body mass (i.e., muscle and bone) with a density of 1.1g/cm3. One limitation of the underlying assumption is the variability in density between muscle and bone; for example, bone has a higher density than muscle, and bone mineral density (BMD) varies with age and other conditions. In addition, the density of body fat may vary, depending on the relative components of its constituents, e.g., glycerides, sterols, and glycolipids.


While the cited techniques assume 2 body compartments, DEXA can estimate 3 body compartments consisting of fat mass, lean body mass, and bone mass. DEXA systems use a source that generates x-rays at 2 energies. The differential attenuation of the 2 energies is used to estimate the bone mineral content and the soft tissue composition. When 2 x-ray energies are used, only 2 tissue compartments can be measured; therefore, soft tissue measurements (i.e., fat and lean body mass) can only be measured in areas in which no bone is present. DEXA also has the ability to determine body composition in defined regions, i.e., in the arms, legs, and trunk. DEXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%. Hydration, however, can vary from 67–85% and can be variable in certain disease states. Other assumptions used to derive body composition estimates are considered proprietary by DEXA manufacturers (i.e., Lunar, Hologic, and Norland.)


Dual x-ray absorptiometry (DEXA) body composition studies are considered investigational.

Policy Guidelines

Category III CPT code 0028T specifically identifies DEXA body composition studies. This code was deleted effective 12/31/08. Starting in 2009, this service should be coded using the unlisted CPT code 76499.

Benefit Application
BlueCard/National Account Issues

State or federal mandates (e.g., FEP) may dictate that all devices approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.


This policy was originally created in 2003 and was updated regularly with searches of the MEDLINE database. The most recent literature search was performed for the period through October 2012. Key studies are described below.

Several different clinical roles for whole body dual x-ray absorptiometry (DEXA) scans to assess body composition have been suggested. Each clinical application requires different data for analysis.

DEXA as Reference Standard for Body Composition Assessment

In general, reference standards for diagnostic tests, often used primarily in research settings, serve to evaluate and verify the use of simpler and more convenient alternative tests that measure the same diagnostic parameter. For body composition studies, underwater weighing (UWW) has been historically considered the reference standard. The emergence of DEXA as a potential new reference standard reflects its ease of use and the fact that it provides a 3-compartment model of body density, i.e., lean body mass, bone mass, and fat mass, compared to the 2-compartment model of UWW. More recently, a 4-compartment model has been suggested as the reference standard, consisting of measurements of bone/mineral, protein, water, and fat. Studies to evaluate different techniques of measuring the same parameter typically consist of correlation studies that compare values between the 2 techniques. However, correlation studies do not provide information on which diagnostic technique more closely represents the true value. For example, a lack of correlation between DEXA and UWW may reflect the lack of accuracy of UWW, as opposed to any deficiency in the DEXA technique. Furthermore, two diagnostic techniques may be highly correlated but produce different values of body composition, i.e., compared to UWW, DEXA may identify different groups of patients as abnormal and normal.

There is extensive literature comparing DEXA to other techniques for assessing body composition, most commonly UWW, bioelectrical impedance, or skin-fold thickness in different populations of patients, i.e., different age groups, ethnicities, and underlying disorders. (1-4) In general, these studies have shown that DEXA is highly correlated to various methods of body composition assessment. Detailed review of this extensive literature is beyond the scope of this discussion; however, it is apparent that many authors would consider a DEXA body composition study the reference standard. For example, in various research studies, the results of DEXA body composition have been included as an intermediate outcome in studies of nutrition and various metabolic disorders. (5-9) Regardless of whether a DEXA scan is considered the reference standard, the key consideration regarding its routine clinical use is if the results of the scan can be used in the management of the patient to improve health outcomes.

DEXA as a Diagnostic Test to Detect Abnormal Body Composition

As a single diagnostic measure, it is important to establish diagnostic cut-off points for normal and abnormal values. This is problematic, since normal values will require the development of normative databases for the different components of body composition (i.e., bone, fat, and lean mass) for different populations of patients at different ages. In terms of measuring BMD, normative databases have largely focused on postmenopausal white women, and these values cannot necessarily be extrapolated to either men or to different races. DEXA determinations of BMD are primarily used for fracture risk assessment in postmenopausal women and to select candidates for various pharmacologic therapies to reduce fracture risk. In addition to the uncertainties of establishing normal values for other components of body composition, it also is unclear how a single measure of body composition would be used in the management of the patient.

DEXA as a Technique to Monitor Changes in Body Composition

Changes in body composition over time may provide useful information. The ability to detect changes is related in part to the precision of the technique, defined as the degree to which repeated measurements of the same variable give the same value. For example, DEXA measurements of bone mass are thought to have a precision error of 1–3%, and given the slow rate of change in body mass index (BMD) in postmenopausal women treated for osteoporosis, it is likely that DEXA scans would only be able to detect a significant change in BMD in the typical patient after 2 years of therapy. Of course, changes in body composition are anticipated to be larger and more rapid than changes in BMD in postmenopausal women; therefore, precision errors in DEXA scans become less critical in interpreting results. Many studies have used DEXA to monitor changes in body composition, and the precision is similar to that estimated for DEXA measurements of BMD. While measuring changes in body composition is widely used in athletes for training purposes, it is still unclear how monitoring changes in body composition could be used in the medical management of the patient.

Additional Studies

The literature reflects extensive use of whole body DEXA to determine body composition in research. Active research areas are comparison of established clinical measures of body composition (body mass index or BMI, anthropomorphic measurements, and bioelectrical impedance analysis) with results using DEXA, and improvement of equations for more accurate clinical assessment of lean and fat body mass. Although refinement of equations may lead to closer agreement with DEXA estimates of fat mass and fat-free mass, for routine clinical use, BMI is considered to provide satisfactory accuracy. (10)

For many clinical indications, DEXA is being used as the reference standard for the development of simpler methods of determining body composition. (11-14) For example, one study found that the Slaughter equation with skin-fold measurements was the closest to DEXA for assessing the body composition of children with cystic fibrosis. (15) In another study, bioelectrical impedance was considered to be a valid diagnostic alternative to DEXA in women with amenorrhea.(16) In patients with human immunodeficiency virus (HIV)-associated lipodystrophy, bioelectrical impedance was found to measure body composition with good precision in comparison with DEXA. (17) Another study reported that a linear regression model incorporating age, weight, height, waistline, and hipline, predicted DEXA body composition with good accuracy and might be developed as a screening method to identify individuals with metabolic dysfunction. (18)

DEXA measurements of body mass continue to be included as outcomes measures in various trials. A few reports suggest that DEXA may have clinical utility for diagnosis of lipodystrophy in patients with HIV, for predicting metabolic insulin sensitivity in older men and women, and for predicting glomerular filtration rate (GFR) in dialysis patients. (19-24) In another study, investigators hypothesized that DEXA would provide more accurate measurement than other methods in conditions, such as chronic obstructive pulmonary disease (COPD), with altered fluid balance. (25) Research in these specific clinical applications of DEXA is at an early stage, and studies have not shown if use of this test in clinical care improves outcomes.


DEXA (dual x-ray absorptiometry) has emerged as a new reference standard for body composition studies, replacing underwater weighing. While DEXA scans have become a valued research tool, it is unclear how information regarding body composition could be used in the active medical management of the patient to improve health outcomes. Periodic literature searches have not identified any controlled studies in which DEXA body composition measurements were actively used in patient management, nor has the utility of DEXA been compared to the use of other simpler techniques of body composition assessment, i.e., bioelectrical impedance or skin-fold thickness, in a clinical setting. None of the studies reported data demonstrating the impact of body composition measurement on health outcomes. The technique is considered investigational.

Technology Assessments, Guidelines and Position Statements

No guidelines or technology assessments on DEXA to determine body composition were found.

Medicare National Coverage

No National Coverage Determination



  1. Kohrt WM. Preliminary evidence that DEXA provides an accurate assessment of body composition. J Appl Physiol 1998; 84(1):372-7.
  2. Laskey MA. Dual-energy X-ray absorptiometry and body composition. Nutrition 1996; 12(1):45-51.
  3. Prior BM, Cureton KJ, Modlesky CM et al. In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol 1997; 83(2):623-30.
  4. Salamone LM, Fuerst T, Visser M et al. Measurement of fat mass using DEXA: a validation study in elderly adults. J Appl Physiol 2000; 89(1):345-52.
  5. Smith DE, Hudson J, Martin A et al. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 2003; 4(1):45-9.
  6. Smith SR, Lovejoy JC, Greenway F et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50(4):425-35.
  7. van den Ham EC, Kooman JP, Christiaans ML et al. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003; 16(2):82-7.
  8. Vendrely B, Chauveau P, Barthe N et al. Nutrition in hemodialysis patients previously on a supplemented very low protein diet. Kidney Int 2003; 63(4):1491-8.
  9. Kamimura MA, Avesani CM, Cendoroglo M et al. Comparison of skinfold thicknesses and bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body fat in patients on long-term haemodialysis therapy. Nephrol Dial Transplant 2003; 18(1):101-5.
  10. U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale. November 2003. Agency for Healthcare Research and Quality, Rockville, MD. Available online at: Last accessed November 2011.
  11. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A et al. Validity and reliability of body composition analysers in children and adults. Br J Nutr 2008; 100(4):859-65.
  12. Kullberg J, Brandberg J, Angelhed JE et al. Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy X-ray absorptiometry. Br J Radiol 2009; 82(974):123-30.
  13. Liem ET, De Lucia Rolfe E, L'Abee C et al. Measuring abdominal adiposity in 6 to 7-year-old children. Eur J Clin Nutr 2009; 63(7):835-41.
  14. Elkan AC, Engvall IL, Tengstrand B et al. Malnutrition in women with rheumatoid arthritis is not revealed by clinical anthropometrical measurements or nutritional evaluation tools. Eur J Clin Nutr 2008; 62(10):1239-47.
  15. Wells GD, Heale L, Schneiderman JE et al. Assessment of body composition in pediatric patients with cystic fibrosis. Pediatr Pulmonol 2008; 43(10):1025-32.
  16. Bruni V, Dei M, Morelli C et al. Body Composition Variables and Leptin Levels in Functional Hypothalamic Amenorrhea and Amenorrhea Related to Eating Disorders. J Pediatr Adolesc Gynecol 2011 Sep 8 [Epub ahead of print].
  17. Siqueira Vasimon H, Jordao AA, Albuquerque de Paula FJ et al. Comparison of bioelectrical impedance with skinfold thickness and X-ray absorptiometry to measure body composition in HIV-infected with lipodistrophy. Nutr Hosp 2011; 26(3):458-64.
  18. Yavari R, McEntee E, McEntee M et al. Anthropometric variables accurately predict dual energy x-ray absorptiometric-derived body composition and can be used to screen for diabetes. PloS One 2011; 6(9):e24017.
  19. Bonnet E, Delpierre C, Sommet A et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitometry 2005; 8(3):287-92.
  20. Lee CC, Glickman SG, Dengel DR et al. Abdominal adiposity assessed by dual energy X-ray absorptiometry provides a sex-independent predictor of insulin sensitivity in older adults. J Gerontol A Biol Sci Med Sci 2005; 60(7):872-7.
  21. Taylor TP, Wang W, Shrayyef MZ et al. Glomerular filtration rate can be accurately predicted using lean mass measured by dual-energy X-ray absorptiometry. Nephrol Dial Transplant 2006; 21(1):84-7.
  22. Asha HS, Seshadri MS, Paul TV et al. HIV lipodystrophy: An objective definition using DXA derived regional fat ratios in a South Asian population. Endocr Pract 2011:1-32.
  23. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33(5):571-6.
  24. Moran SA, Patten N, Young JR et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004; 53(4):513-9.
  25. Miller A, Strauss BJ, Mol S et al. Dual-energy X-ray absorptiometry is the method of choice to assess body composition in COPD. Respirology 2009; 14(3):411-8.




CPT 76499 Unlisted diagnostic radiographic procedure
ICD-9 Diagnosis   Investigational for all diagnoses
ICD-10-CM (effective 10/1/14)   Investigational for all diagnoses
ICD-10-PCS (effective 10/1/14)   ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this imaging.
  BW0KZZZ, BW0LZZZ Imaging, anatomical regions, plain radiography, codes for whole body or whole skeleton

Body Composition, DEXA
Body Composition, DXA
DEXA, Body Composition
DXA, Body Composition
Whole Body Dual X-Ray Absorptiometry
Dual-Energy X-Ray Absorbtiometry

Policy History

Date Action Reason
07/17/03 Add policy to Radiology section New policy
11/9/04 Replace policy Policy updated with literature review; policy statement unchanged
08/17/05 Replace policy Policy updated with literature review; policy statement unchanged
02/15/07 Replace policy Policy updated with literature review; reference numbers 12 to 15 added; policy statement unchanged
06/12/08 Replace policy Policy updated with literature review; reference numbers 16-18 added; policy statement unchanged
12/11/08 Replace policy - coding update only CPT coding updated
02/11/10 Replace policy Policy updated with literature review; reference numbers 19-23 added; policy statement unchanged
12/9/10 Replace policy - coding update only ICD-10 codes added to policy.
03/10/11 Replace policy Policy updated with literature review, rationale section extensively edited, some references renumbered or removed, no changes in policy statement
12/08/11 Replace policy Policy updated with literature review through October 2011, references added and reordered, policy statement unchanged
12/13/12 Repalce Policy
Policy updated with literature review through October 2012. No new references added. Policy statement unchanged